Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
328 hedge funds and large institutions have $5.19B invested in Amedisys in 2022 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 127 increasing their positions, 91 reducing their positions, and 56 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 91
14% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 56
10% more capital invested
Capital invested by funds: $4.72B → $5.19B (+$473M)
3.11% more ownership
Funds ownership: 89.76% → 92.87% (+3.1%)
1% more funds holding
Funds holding: 324 → 328 (+4)
8% more call options, than puts
Call options by funds: $57.2M | Put options by funds: $52.8M
Top Buyers
Top Sellers
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$63.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$49M |
| 3 |
D.E. Shaw & Co
New York
|
-$33.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$30.5M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
-$25.1M |
AMED Hedge Fund Activity: Q1 2022 in Review
328 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2022, worth a combined $5.19B — up 10% from $4.72B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new AMED positions and 56 closed out — a net gain of 8 holders — while 127 added to existing stakes and 91 trimmed.
The largest buyer was Mackenzie Financial, adding an estimated $57.7M. The largest seller was Viking Global Investors, exiting entirely with an estimated $63.3M sold.
- 328 institutional investors held Amedisys (AMED) as of Q1 2022, up from 324 in Q4 2021.
- Funds reported $5.19B of Amedisys stock for Q1 2022, up 10% quarter-over-quarter.
- 64 funds opened new Amedisys positions in Q1 2022 and 56 closed out, a net change of +8 holders.
- The largest Amedisys buyer in Q1 2022 was Mackenzie Financial, an estimated $57.7M added.
- The largest Amedisys seller in Q1 2022 was Viking Global Investors, an estimated $63.3M sold.
Based on aggregated 13F filings for Q1 2022.